Austrianni GmbH is a new biotechnology company founded in 2015. Its mission is to develop novel antibody-based therapeutics for the prevention and treatment of tuberculosis and other important infectious diseases.

Tuberculosis represents a major global health concern that kills more than a million people each year and significantly incapacitates up to ten times more than this. While it is currently most prevalent in low-income countries, cases arise everywhere. Drug-resistant forms of the disease are a major emergent concern especially in Central Asia and Eastern Europe, but the potential for these to become even more widespread is substantial. Despite decades of concerted research, no effective vaccine for tuberculosis has yet been developed, and the most widely used drugs to treat it remain limited by toxicity and other problems.